FundaMental Pharma is engaged in pioneering research around a breakthrough molecular mechanism that allows to safely counteract glutamate neurotoxicity (also known as excitotoxicity) by specifically targeting the interface between NMDA receptors and TRPM4 channels with small molecule TwinF interface inhibitors (Yan et al., Science 2020). TwinF interface inhibitors constitute an entirely new class of drugs that safely ameliorate glutamate neurotoxicity, a common cause of neurodegeneration. Our initial focus is on amyotrophic lateral sclerosis (ALS). The applicability of our molecules extends to a range of neurogenerative disorders including Alzheimer’s disease (AD).
Company Details
- Employees
- 11
- Founded
- -
- Address
- Im Neuenheimer Feld 582, Heidelberg,baden-Württemberg 69120,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://fundamentalpharma.com/
- HQ
- Heidelberg, Baden-Württemberg
Fundamental Pharma Questions
Fundamental Pharma's website is https://fundamentalpharma.com/
Fundamental Pharma's LinkedIn profile is https://de.linkedin.com/company/fundamental-pharma
Fundamental Pharma has
11 employees.
View email and phone details for 11
employees at Fundamental Pharma.
Fundamental Pharma's industry is
Biotechnology Research
Fundamental Pharma's top competitors are
Phialogics - The Native Biologics Platform Company,
Anavo Therapeutics Bv,
Athira Pharma,
Biomed X Institute,
Mayr Biomedtech Consulting,
Boehringer Ingelheim,
Biolabs Heidelberg,
Esobiotec,
Incephalo,
Asceneuron Sa.
Fundamental Pharma's categories are Biotechnology Research
Fundamental Pharma's founding year is 2016
